Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy.
Abstract details
Antitumor characterization of IPH6501, a novel il2v-armed tetraspecific NK cell engager targeting CD20 B cells, in DLBCL and FL patient samples, and in preclinical combination with R-CHOP Abstract Code: PS2004Session: Poster session 2Session Date/Time: Saturday, June 14, 2025, 18:30 – 19:30 CESTMore information can be found on the EHA website.
In addition, an abstract related to SAR'514/IPH6401 (developed by Sanofi) was accepted for online publication.
The BCMA NK Cell Engager SAR'514 Induces Macrophage-Mediated Phagocytosis which is improved by combination with Evorpacept, a CD47 Blocker, in Multiple Myeloma Abstract Code: PB2850
About ANKET®
ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.
About IPH6501
IPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16), IL-2R (but not the alpha subunit) through a variant of human IL-2, and a tumor antigen (CD20) via a single molecule, hence providing proliferation and activation signals targeted to NK cells and promoting their cytotoxic activity against CD20 expressing malignant cells.
IPH6501 has shown better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models (Demaria, EHA 2023, Carrette, SITC 2024, Demaria et al, Science Immunology 2024).
IPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with relapsed and/or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com. Follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code Ticker code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including "anticipate," "believe," "can," "could," "estimate," "expect," "may," "might," "potential," "intend," "should," "will," or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250514267623/en/
Contacts
For additional information, please contact:
Investors Innate Pharma Henry WheelerTel.: +33 (0)4 84 90 32 88Henry.wheeler@innate-pharma.fr
Media Relations NewCap Arthur RouilléTel.: +33 (0)1 44 71 00 15innate@newcap.eu
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 minutes ago
- Business Wire
Tineco Introduces the New FLOOR ONE S7 Stretch Steam: Steam at the Service of Well-being
PARIS--(BUSINESS WIRE)--Tineco, a pioneer in intelligent cleaning solutions, unveils its latest innovation, the FLOOR ONE S7 Stretch Steam. This next-generation vacuum mop combines the natural power of 140 °C steam with an ultra-flexible design and smart technologies. Designed for modern households, this new device cleans and disinfects floors without chemicals, using steam alone. An ecological, effective, and healthy solution that becomes the perfect daily ally for a clean home, even with children or pets. Thanks to its ultra-flat 180° swivel head, it easily slips under low furniture. Its smart sensors automatically adjust the power according to the dirt level for optimal cleaning. No more scrubbing, rinsing, or drying — the FLOOR ONE S7 Stretch Steam does it all by itself. A concentration of technologies for optimal cleaning: HyperSteam steam at 140 °C: removes stains, bacteria, and naturally disinfects Ultra-flat 180° head: perfect for cleaning under low furniture without moving anything Up to 80 minutes autonomy: clean an entire floor without recharging DualBlock™ anti-tangle system: stops hair and fur to prevent blockages Automatic brush cleaning and drying: silent, fast, and hygienic iLoop™ smart sensors: adjust suction power in real time based on dirt levels 3-sided edge cleaning: efficiently reaches baseboards and corners Availability and Pricing The FLOOR ONE S7 Stretch Steam is available now on Amazon France and the official Tineco online store, with a recommended retail price of 699€. The FLOOR ONE S7 Stretch Steam Plus version will be available from early October in Fnac Darty and Boulanger stores, with a recommended retail price of 699 €. Visuals available here About Tineco Tineco ("tin-co") was founded in 1998 with its first product launch as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has evolved into a global leader in intelligent appliances spanning floor care, kitchen, and personal care categories. With a growing user base of over 19.5 million households and availability in approximately 30 countries worldwide, Tineco remains committed to its brand vision of making life easier through smart technology and continuous innovation. For more information, visit
Business Wire
an hour ago
- Business Wire
Andong Jongga Culture Center to Export Fermented Teas via Mongolian-Gyeongbuk Trade Delegation
ANDONG, South Korea--(BUSINESS WIRE)--The Andong Jongga Culture Center has announced that it will export its fermented teas—ginger and apple—to overseas supermarkets through the Mongolian-Gyeongbuk Comprehensive Trade Delegation. These teas, either patented or patent-pending, are recognized for their exceptional flavor and proven health benefits. 'We plan to continue researching a variety of fermented teas that can serve as nourishing everyday beverages — even as a healthy alternative to water.' Share The fermented ginger tea is particularly noted for its ability to boost immunity and alleviate conditions such as rhinitis and gastritis. Thanks to its high absorption rate, many users report noticeable effects with just a few servings. Its portability and absence of side effects have further strengthened consumer trust. Soonja Lee from the Andong Jongga Culture Center stated, 'We plan to continue researching a variety of fermented teas that can serve as nourishing everyday beverages—even as a healthy alternative to water.' About Andong Jongga Culture Center Since its founding in October 2017, the Andong Jongga Cultural Center has been dedicated to developing and producing premium goods rooted in time-honored traditions passed down through families. By harnessing the richness of local agricultural ingredients—most notably Andong ginger—the center is elevating the value and global appeal of Korea's regional specialties.
Yahoo
an hour ago
- Yahoo
Nordson (NDSN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Manufacturing company Nordson (NASDAQ:NDSN) will be reporting results this Wednesday afternoon. Here's what to look for. Nordson beat analysts' revenue expectations by 1.1% last quarter, reporting revenues of $682.9 million, up 5% year on year. It was a satisfactory quarter for the company, with EPS guidance for next quarter topping analysts' expectations but organic revenue in line with analysts' estimates. Is Nordson a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Nordson's revenue to grow 9.1% year on year to $721.7 million, improving from the 2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.63 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nordson has missed Wall Street's revenue estimates three times over the last two years. Looking at Nordson's peers in the professional tools and equipment segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lincoln Electric delivered year-on-year revenue growth of 6.6%, beating analysts' expectations by 5.1%, and Hillman reported revenues up 6.2%, topping estimates by 2.6%. Lincoln Electric traded up 7.8% following the results while Hillman was also up 22.9%. Read our full analysis of Lincoln Electric's results here and Hillman's results here. There has been positive sentiment among investors in the professional tools and equipment segment, with share prices up 4.8% on average over the last month. Nordson's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $251.80 (compared to the current share price of $215.93). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
